Medicenna Therapeutics Corp (MDNA) Price & Analysis

Compare

209 Followers

MDNA Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$0.78 - C$2.63

Previous CloseN/A

Volume26.49K

Average Volume (3M)29.82K

Market Cap

C$62.52M

Enterprise ValueC$23.37M

Total Cash (Recent Filing)C$30.00M

Total Debt (Recent Filing)C$174.00K

Price to Earnings (P/E)―

Beta1.51

Next Earnings

Aug 07, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding68,697,876

10 Day Avg. Volume24,554

30 Day Avg. Volume29,816

Financial Highlights & Ratios

PEG Ratio-0.35

Price to Book (P/B)1.93

Price to Sales (P/S)0.00

P/FCF Ratio-4.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$5.96

Price Target Upside554.95% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Medicenna Therapeutics Corp News

PremiumCompany Announcements

Medicenna Reports Promising Fiscal 2025 Results and Advances in Immunotherapy Programs

11d ago

PremiumPre-Earnings

MDNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

14d ago

PremiumCompany Announcements

Medicenna Unveils Promising Preclinical Results for Novel Cancer Therapy

2M ago

PremiumRatings

Promising Clinical Trial Results Boost Buy Rating for Medicenna Therapeutics Corp

2M ago

PremiumCompany Announcements

Medicenna’s MDNA11 Shows Promising Results in Cancer Trial

2M ago

PremiumCompany Announcements

Medicenna to Present at 2025 Healthcare Investor Conference

3M ago

PremiumCompany Announcements

Medicenna to Present at Healthcare Innovation Conference

3M ago

PremiumCompany Announcements

Medicenna to Present Key Updates at AACR 2025

3M ago

See All TSE:MDNA News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe first complete response was reported in the combination dose escalation phase of the study in a patient with advanced anal squamous cell carcinoma.

Financial StabilityThe cash runway for Medicenna Therapeutics extends into mid-calendar 2026, supporting its financial stability.

Regulatory PathwaysManagement hopes to further validate the positive signal in these cancers, with potential to pursue an accelerated approval path.

Bears Say

Data SufficiencyThe overall response rate in the combination arm is considered low, highlighting the need for more data.

Efficacy DataAlthough the combo data is promising, it is too early to determine efficacy.

Response RatesThe overall response rate for the Medicenna pembro combo in solid tumors is low at 22%.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

9.13% Insiders

―

Mutual Funds

0.17% Other Institutional Investors

90.70% Public Companies and

Individual Investors

Detailed Ownership Overview >

MDNA FAQ

What was Medicenna Therapeutics’s price range in the past 12 months?

Medicenna Therapeutics lowest stock price was C$0.78 and its highest was C$2.63 in the past 12 months.

What is Medicenna Therapeutics’s market cap?

Medicenna Therapeutics’s market cap is C$62.52M.

When is Medicenna Therapeutics’s upcoming earnings report date?

Medicenna Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 31 days.

How were Medicenna Therapeutics’s earnings last quarter?

Medicenna Therapeutics released its earnings results on Jun 26, 2025. The company reported C$0.02 earnings per share for the quarter, beating the consensus estimate of -C$0.06 by C$0.08.

Is Medicenna Therapeutics overvalued?

According to Wall Street analysts Medicenna Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicenna Therapeutics pay dividends?

Medicenna Therapeutics does not currently pay dividends.

What is Medicenna Therapeutics’s EPS estimate?

Medicenna Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicenna Therapeutics have?

Medicenna Therapeutics has 68,697,876 shares outstanding.

What happened to Medicenna Therapeutics’s price movement after its last earnings report?

Medicenna Therapeutics reported an EPS of C$0.02 in its last earnings report, beating expectations of -C$0.06. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Medicenna Therapeutics?

Currently, no hedge funds are holding shares in TSE:MDNA

Medicenna Therapeutics Corp Stock Smart Score

Underperform

Fundamentals

Return on Equity

-97.22%

Trailing 12-Months

Asset Growth

48.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medicenna Therapeutics

Medicenna Therapeutics Corp (MDNA) is a clinical-stage immunotherapy company focused on the development and commercialization of highly selective engineered cytokines for cancer treatment. Operating within the biotechnology sector, Medicenna's core products include a pipeline of Superkines and Empowered Cytokines designed to enhance the immune system's ability to fight cancer. The company's proprietary approach aims to develop therapies that can selectively stimulate or inhibit specific receptor pathways associated with various cancers.

MDNA Stock 12 Month Forecast

Average Price Target

C$5.96

▲(554.95%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"C$4","9":"C$9","-1":"-C$1","1.5":"C$1.5","6.5":"C$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$8.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$5.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$3.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Nov<br/>2023","9":"Aug<br/>2024","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.97,1.5238461538461539,2.077692307692308,2.6315384615384616,3.1853846153846153,3.739230769230769,4.2930769230769235,4.846923076923077,5.400769230769231,5.954615384615384,6.508461538461538,7.062307692307693,7.616153846153846,{"y":8.17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.97,1.353846153846154,1.7376923076923076,2.121538461538462,2.5053846153846155,2.8892307692307693,3.273076923076923,3.6569230769230767,4.0407692307692304,4.424615384615384,4.808461538461538,5.192307692307692,5.576153846153846,{"y":5.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.97,1.1838461538461538,1.3976923076923078,1.6115384615384616,1.8253846153846154,2.039230769230769,2.2530769230769234,2.466923076923077,2.680769230769231,2.894615384615385,3.1084615384615386,3.3223076923076924,3.536153846153846,{"y":3.75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.99,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.22,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >